TY  - JOUR

T1  - Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

JO  - Ann Rheum Dis

PY  - 2005/07/01

AU  - Bansback NJ

AU  - Brennan A

AU  - Ghatnekar O

ED  - 

DO  - DOI: 10.1136/ard.2004.027565

VL  - 64

IS  - 7

SP  - 995

EP  - 1002

Y2  - 2024/09/20

ER  -